ICOS and neoplasm: We provide novel mechanistic insight into the complex immune modulation that occurs in response to a FAK inhibitor, identifying not only changes in immune cell recruitment to tumors, but also in the expression of molecular pathways including PD-L2 and ICOS that fine tune the efficacy of the anti-tumor T-cell response.